NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date (Descending) | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
50090-1015-00 | 50090-1015 | ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 28, 2014 | March 31, 2019 | In Use |
50090-1015-01 | 50090-1015 | ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 28, 2014 | March 31, 2019 | In Use |
50090-1015-02 | 50090-1015 | ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 28, 2014 | March 31, 2019 | In Use |
50090-1015-03 | 50090-1015 | ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 28, 2014 | March 31, 2019 | In Use |
50090-1015-04 | 50090-1015 | ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 28, 2014 | March 31, 2019 | In Use |
51862-0084-14 | 51862-0084 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | March 31, 2019 | In Use |
51862-0084-51 | 51862-0084 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | March 31, 2019 | In Use |
51862-0086-14 | 51862-0086 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | March 31, 2019 | In Use |
51862-0086-51 | 51862-0086 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | March 31, 2019 | In Use |
51991-0922-98 | 51991-0922 | Oxaliplatin | Oxaliplatin | 50.0 mg/10mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 22, 2017 | March 31, 2019 | No Longer Used |
51991-0937-98 | 51991-0937 | Paclitaxel | Paclitaxel | 100.0 mg/16.7mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 22, 2017 | March 31, 2019 | No Longer Used |
55292-0911-51 | 55292-0911 | Mechlorethamine hydrochloride | Mustargen | 10.0 mg/10mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intracavitary, Intravenous | March 15, 1949 | March 31, 2019 | No Longer Used |
00703-4434-11 | 00703-4434 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 100.0 mg/5mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb. 28, 2008 | March 31, 2019 | No Longer Used |
00703-5043-01 | 00703-5043 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sept. 1, 1995 | March 31, 2019 | No Longer Used |
00703-5043-03 | 00703-5043 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sept. 1, 1995 | March 31, 2019 | No Longer Used |
00024-5917-01 | 00024-5917 | Clofarabine | Clolar | 1.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | July 1, 2017 | March 31, 2019 | In Use |
50090-1922-00 | 50090-1922 | Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 4.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-Articular, Intra-articular, Intralesional, IM, IV, Intralesional, Intramuscular, Intravenous, Soft Tissue | July 15, 2015 | March 31, 2019 | In Use |
43063-0208-01 | 43063-0208 | Hydrocortisone | Hydrocortisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 23, 2009 | March 29, 2019 | In Use |
43063-0208-30 | 43063-0208 | Hydrocortisone | Hydrocortisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 23, 2009 | March 29, 2019 | In Use |
50242-0918-86 | 50242-0918 | Atezolizumab | TECENTRIQ | 840.0 mg/14mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | March 8, 2019 | March 18, 2019 | In Use |
70518-0291-00 | 70518-0291 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 8, 2017 | March 14, 2019 | In Use |
70255-0020-01 | 70255-0020 | Encorafenib | BRAFTOVI | 50.0 mg/1 | Chemotherapy | BRAF Inhibitor | V600E | Oral | June 27, 2018 | March 13, 2019 | In Use |
68001-0247-55 | 68001-0247 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 13, 2018 | March 13, 2019 | In Use |
70518-1881-00 | 70518-1881 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Feb. 19, 2019 | March 8, 2019 | No Longer Used | |
00143-9739-05 | 00143-9739 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 3, 2009 | March 5, 2019 | No Longer Used |
Found 10,000 results in 3 milliseconds — Export these results